Postmarket Drug Safety Information for Patients and Providers
In accordance with Section 915 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), this website contains links to postmarket drug safety information to improve transparency and communication to patients and healthcare providers.
Risk Evaluation and Mitigation Strategies (REMS)
- List of REMS
- Federal Register Notice: Identification of Drug and Biological Products Deemed to Have Risk Evaluation and Mitigation Strategies for Purposes of the Food and Drug Administration Amendments Act of 2007.
Studies and Clinical Trials of Approved Products Required by FDA or Agreed to by the Application Holder
Registries and Clinical Trials
- Clinicaltrial.gov Registry and Results Databank ClinicalTrials.gov is a registry of federally and privately supported clinical trials conducted in the United States and around the world. These trials are designed primarily to evaluate the premarket efficacy and safety of drugs and biologics, as well as for new indications for products currently marketed.
Memorandum of Agreement Between the Office of New Drugs and the Office of Surveillance and Epidemiology in the Center for Drug Evaluation and Research
Latest Safety Information
Reporting Problems to the FDA
Warnings and Recalls
Regulations and Guidance Documents
Information about FDA's Drug Safety Oversight Board (DSB)
Using Medicines Safely
Consumer Articles on Drug Safety
General Health Information
- MedlinePlus Authoritative drug and health information from the National Institutes of Health (NIH), and other government agencies and health-related organizations.
FDA's Response to the Institute of Medicine's 2006 Report
to Top Back to CDER home
PDF requires the free Adobe Acrobat Reader
Date created: October 15, 2008, updated December 5, 2008